

Diagnosis of Chronic Granulomatous Disease in an Adult Patient with Probable Miliary MDR Tuberculosis

Martha Lada*; Katerina Manika; Kleopatra Spanou; Maria Kipourou; Marianna Tzanoudaki; Christina Manika; Maria Kanariou; Ioannis Kioumis

*Martha Lada

Pulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Exohi, Thessaloniki, 57010, Greece

Fax: 00 30 23 1330 7253; Email: marthalada@otenet.gr

Abstract

Chronic granulomatous disease is a rare inherited disease characterized by severe recurrent bacterial and fungal infections beginning in childhood.

In this report, we describe a case of a 27-year old man with persisting fever, leukocytosis and micronodular image in chest x-ray. The patient showed no response to multiple therapeutic approaches until the addition of second line antituberculous drugs. He eventually showed clinical improvement with that treatment even though all cultures (sputum, BAL, gastric fluid) for Mycobacteria were negative. Because of his unsatisfactory response to treatment and his long history of infections, investigation for Primary Immunodeficiency was performed and autosomal chronic granulomatous disease (CGD) was diagnosed.

Clinicians should consider chronic granulomatous disease as possible background in cases of severe infections in the setting of a medical history of recurrent infections. Furthermore, tuberculosis should be included in the differential diagnosis of infection for patients with chronic granulomatous disease.

Keywords

chronic granulomatous disease; immunodeficiency; tuberculosis; neutrophil disorder

Introduction

The neutrophilic granulocyte is an important cellular component of the innate immune system. For a pathogen to be neutralized, it has to be recognized, phagocytosed, and destroyed by lytic enzymes contained in the neutrophil's granules and reactive oxygen species formed by the enzyme complex NADPH oxidase [1]. In general, lack of functional neutrophils in an individual may lead to infections with *Staphylococcus aureus*, gram-negative organisms such as *Pseudomonas aeruginosa* and *Burkholderia cepacia*, the gram-positive bacterium *Nocardia asteroides*, as well as fungal infections such as *Aspergillus* spp. and *Candida* spp [2,3].

Chronic granulomatous disease (CGD) is a rare genetic disorder, occurring in about one in 250,000 individuals [2]. In Greece it is estimated at 0.90 (95% CI 0.89-0.91) per 100,000 live births in the last decade [4]. It is the most frequent neutrophil function disorder, and is caused by a defective NADPH oxidase enzyme complex which is inherited either in X-linked or one of three existing autosomal recessive

forms [5]. As a result, phagocytosed microorganisms can not be effectively killed, resulting in formation of granulomata [6]. The mostly affected organs are the lungs, skin, gastrointestinal tract, lymph nodes, and liver [7]. Surprisingly, at most clinical cases, no causative pathogen can be isolated, despite the underlying microbial infections [2]. The disorder is caused by a defect in any of the four subunits of the leukocyte NADPH oxidase, gp91phox and p22phox, located in membranes, as well as two cytosolic oxidase components, p47phox and p67phox. Mutations in the gp91phox gene are caused by the X-linked recessive form of the disease that affects the majority of CGD patients (about 70% and most of them males) [8]. The remaining 30% of disease cases is inherited in an autosomal recessive manner, in which males and females are equally affected. These patients have mutations in the genes encoding the other three subunits and may be associated with milder disease [2,9].

The term miliary tuberculosis (TB) refers to any progressive widespread dissemination of *Mycobacterium tuberculosis* via hematogenous spread. Classic miliary TB is defined as milletlike (mean, 2 mm; range, 1-5 mm) seeding of TB bacilli in the lung, as evidenced on chest radiography. This pattern is seen in 1-3% of all TB cases. It is a potentially lethal disease if not diagnosed and treated early [10,11].

We report the case of a young man who was diagnosed with CGD during his hospitalization for possible miliary multi-drug resistant (MDR)-TB.

Case Presentation

A 27-year old man was transferred to our department after one week in a regional hospital due to persisting fever, fatigue, anorexia, weight loss, tachycardia and abnormal chest x-ray. He had been treated for community acquired pneumonia with ampicillin-sulbactam and azithromycin but showed no clinical or radiological improvement.

The patient was smoker, HCV positive, HIV negative, former iv heroin user and current cannabis smoker. Regarding his medical record, he had been diagnosed with prostatitis and treated with ciprofloxacin for 20 days until one month before admission to the regional hospital. He also had a history of meningitis at the age of nine years, for which he had empirically received antituberculous agents.

On admission his clinical examination revealed white skin lesions from past Staphylococcus infection on the spots of intravenous heroin injections. The patient presented with tachycardia (125 bpm), hypoxemia ($PO_2=62\text{mmHg}$) and fatigue. The white blood cell count (WBC) ($27000 \times 10^9/l$, 87% neutrophils, 12% lymphocytes), erythrocyte sedimentation rate (85mm/h) and levels of C-reactive protein (15mg/l) were elevated. Mantoux test was negative. His chest x-ray on admission showed a micronodular pattern compatible with miliary tuberculosis and was confirmed by a chest Computer Tomography (CT) scan (Figure 1). Heart ultrasonography and the ophthalmic examination were normal. Based on the typical radiological pattern, antituberculous treatment was initiated (rifampicin 600mg, isoniazid 300mg, ethambutol 1250mg and pyrazinamide 1500mg).

A week after admission fever and leukocytosis persisted. The sputum and gastric fluid sample were Ziehl-Nielsen and AMTD (Amplified *Mycobacterium Tuberculosis* Direct) test negative and cultures of blood, urine and stool specimens for common pathogens were also negative. In addition serological tests for CMV, EBV, HSV1 and 2, VZV, Widal, Wright, *Rickettsia mooseri*, RSV, *Coxiella burnetti*, *Chlamydomphila psittachi*, *Chlamydiphilla pneumonia*, *Mycoplasma pneumonia*, Adenoviruses were negative for recent infection. The patient was also submitted to bronchoscopy for bronchoalveolar lavage

(BAL) which was negative for *Aspergillus fumigatus* complex antigen (galactomannan), *Nocardia* and *Pneumocystis*. Meropenem and vancomycin was added to his treatment for a possible hospital-acquired pneumonia. After one week amphotericin was also added to his regimen.

At that time, investigation of immune parameters, focused on T-lymphocytes was conducted in peripheral blood and BAL samples (Table 1). The percentage and total number of T and B lymphocytes were normal, while NK lymphocytes were at reduced levels (64/ μ L). An inversed ratio of CD4+/CD8+ lymphocytes was observed but absolute number of each subpopulation was within normal limits. The patient was also submitted to bone marrow biopsy which revealed increased number of eosinophils, sea blue mast cells and plasmocytes 5%.

The adequacy of polymorphonuclear cells (PMNs) NADPH oxidative burst mechanisms was measured by the Dihydrorhodamine (DHR) assay. The DHR reducing activity of the patient's PMA (Phorbol-myristate-acetate) primed PMNs, was non detectable. On the contrary the patient's mother demonstrated a lower than normal activity with a single curve pattern, which was not compatible with X-linked defect. Indeed, the patient's PMNs showed a normal gp91phox expression whereas the p47phox subunit was not detected by Western Blot analysis (Figure 2). This result was confirmed by DNA sequence analysis (c.75_76delGT in NCF1 gene).

Due to the patient's deterioration, second-line antituberculous agents were empirically added (amikacin 900mg, levofloxacin 750mg, and cycloserin 750mg), while amphotericin, meropenem and vancomycin were discontinued. Five days later fever was resolved and WBC decreased. The patient was discharged after 65 days, afebrile, clinically stable with an improving chest x-ray (Figure 3) and WBC count. He was referred to the National Immunological Department Center for Primary Immunodeficiencies for further management of his CGD. Cultures for *M. tuberculosis* were repeatedly negative. Five months after discharge a significant improvement in his chest CT scan was observed. The patient was treated for 18 months (6 months of amikacin) and remained clinically and radiologically stable.

Discussion

Chronic granulomatous disease (CGD) is a primary immunodeficiency that affects phagocytes and leads to recurrent or persistent intracellular bacterial and fungal infections and to granuloma formation [12]. The diagnosis of CGD is usually established during the first years of life with a mean age for the autosomal recessive form of 8.8 years for Europe [2]. There are indeed a few reports about cases with first diagnosis of CGD in adulthood [13,14,15]. The delayed diagnosis in our patient at the age of 27 could be attributed to his autosomal disorder due to which he had a milder course, even though he had been at high risk for infections because of his drug abuse.

The diagnosis of infection by *M. tuberculosis* is challenging, especially in patients with underlying immunodeficiency. Our patient had a history with TB meningitis in childhood which could support the aspect of Mycobacterium infection. His chests X-ray as well as the computer tomography scan were highly diagnostic for miliary TB. Moreover, a miliary pattern has not been described in patients with CGD diagnosed with other severe bacterial or fungal pulmonary infection [16,17]. In addition, it is quite interesting that even though a positive culture for *M. tuberculosis* was never obtained, our patient had undoubtable clinical and imaging improvement with second-line anti-TB treatment. Thus, even though

the diagnosis of TB was not clearly established, continuation of treatment for MDR-TB for 18 months was decided, based on the patient's medical history and clinical outcome. The reported incidence of tuberculosis in 2013 Greece was 5 cases per 100 000 people (WHO report). MDR cases represented the 1.5% of new cases and 9.1% of retreatment cases [18].

In the largest cohort of European CGD patients to date [2], susceptibility to *M. tuberculosis* or atypical mycobacteria was not reported. However, the investigators [2] referred to a number of recent reports, some of which had at that time not been published and claimed there is indeed an increased susceptibility for mycobacterial infection in CGD [19,20]. In addition, in a brief report Lau et al observed that *M. tuberculosis* caused persistent infection and chronic exaggerated inflammation in the lung but not in other organs, such as the spleen, in six patients with CGD [21]. The investigators also suggested that patients with CGD are susceptible to TB and BCG complications and that oxidative burst is probably important in host defense against mycobacterial infections. Moreover, according to a recent report, CGD patients are sensitive to infection with the vaccinal BCG strain which based on the literature is by far the most common mycobacterial disease in these patients [22]. The latest review on pulmonary manifestations, a retrospective study from France in adults with CGD, refers to cases typical and atypical mycobacteria as the identified pathogen [17]. Thus, the older view that the phagocyte NADPH oxidase does not interfere with the defense against mycobacteria, the *in vivo* participation of neutrophils in the mycobacterial host defense and the susceptibility of CGD patients to mycobacterial infections are still questioned [23].

The present case is noteworthy firstly because the age of CGD diagnosis was above the expected and secondly due to the impressive improvement with second-line antituberculous agents, which supports the diagnosis of TB infection despite lack of laboratory confirmation. The diagnosis of CGD should be considered in the investigation of an underlying immunodeficiency even for adult patients. In addition, TB should be included in the differential diagnosis in patients with CGD.

Figures



Figure 1: Patient's chest x-ray and CT scan on admission.




Figure 2: No increase in fluorescence intensity was observed post PMA stimulation, a finding indicating deficiency of the oxidative burst mechanisms




Figure 3: Patient's chest x-ray on discharge.

Table

Cells	Blood	Bal
Cd3+	75.40%	97%
Cd19+	18.83%	1%
CD3-CD16+56+	3.09%	2%
CD3+CD4+	24.43%	40%
CD3+CD8+	46.71%	60%
CD4+/CD8+	0.52	0.67
CD3+CD16+56+	17,00%	7%

Table 1: T-lymphocytes population in patient peripheral blood and BAL samples

References

1. van den Berg JM and Kuijpers TW. Defects in number and function of neutrophilic granulocytes causing primary immunodeficiency. *Eur J Pediatr* 2011;170:1369–76.
2. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. *PLoS One* 2009;4:e5234.
3. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. *Rev Mol Med* 2000;79:170–200.
4. Raptaki M, Varela I, Spanou K, Tzanoudaki M, Tantou S, Liatsis M, et al. Chronic granulomatous disease: a 25-year patient registry based on a multistep diagnostic procedure, from the referral center for primary immunodeficiencies in Greece. *J Clin Immunol* 2013;33:1302-9.
5. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. *Front Immunol* 2014;5:162.
6. Johnston RB Jr. Clinical aspects of chronic granulomatous disease. *Curr Opin Hematol* 2001;8:17–22.
7. Kuijpers T and Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. *Cell Mol Life Sci* 2012;69:7–15.
8. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. *Curr Opin Immunol* 2003;15:578–84.
9. Winkelstein JA, Marino MC, Johnston RB Jr., et al. Chronic granulomatous disease: report on a national registry of 368 patients. *Medicine (Baltimore)*. 2000;79:155-69.
10. American Thoracic Society, US Centers for Disease Control and Prevention. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* 2000;161:1376-95.
11. Mert A, Bilir M, Tabak F, Ozaras R, Ozturk R, Senturk H, et al. Miliary tuberculosis: clinical manifestations, diagnosis and outcome in 38 adults. *Respirology* 2001;6:217-24.
12. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. *Clin Dev Immunol* 2012;252460.

13. Burns DA, Sarkany I. Chronic granulomatous disease in an adult. *J R Soc Med.* 1979;72:139-42.
14. Schapiro BL, Newburger PE, Klempner MS, Dinauer MC. Chronic granulomatous disease presenting in a 69-year-old man. *N Engl J Med.* 1991;325:1786-90.
15. Mansoor D, Roobahany NA, Mazinany H, Samimagam A. Chronic *Fusarium* infection in an adult patient with undiagnosed chronic granulomatous disease. *Clin Infect Dis.* 2003;37:107-8.
16. Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. *Clin Infect Dis.* 2007;45:673-81.
17. Salvator H, Mahlaoui N, Catherinot E, Rivaud E, Pilmis B, Borie R, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. *Eur Respir J.* 2015 Jun;45:1613-23.
18. <http://www.who.int/tb/country/data/profiles/en/>. Last assessed in 29/09/2015
19. Bustamante J, Aksu G, Vogt G, de Beaucoudrey L, Genel F, Chappier A, et al. BCGosis and tuberculosis in a child with chronic granulomatous disease. *J Allergy Clin Immunol* 2007;120: 32–38.
20. Lee PP, Chan KW, Jiang L, Chen T, Li C, , et al. Susceptibility to Mycobacterial Infections in Children With X-Linked Chronic Granulomatous Disease: A Review of 17 Patients Living in a Region Endemic For Tuberculosis. *Pediatr Infect Dis J* 2008;27: 224-30.
21. Lau YL, Chan GC, Ha SY, Hui YF, Yuen KY. The role of phagocytic respiratory burst in host defense against *Mycobacterium tuberculosis*. *Clin Infect Dis* 1998;26:226-7.
22. Deffert C, Schappi MG, Pache JC, Cachat J, Vesin D, Bisig R, et al. *Bacillus calmette-guerin* infection in NADPH oxidase deficiency: defective mycobacterial sequestration and granuloma formation. *PLoS Pathog* 2014;10:e1004325.
23. Lowe DM, Redford PS, Wilkinson RJ, O'Garra A, Martineau AR. Neutrophils in tuberculosis: friend or foe? *Trends Immunol* 2012;33:14–25.

Manuscript Information: Received: July 07, 2016; Accepted: November 11, 2016; Published: November 15, 2016

Authors Information: Martha Lada^{1*}; Katerina Manika¹; Kleopatra Spanou²; Maria Kipourou¹; Marianna Tzanoudaki²; Christina Manika³; Maria Kanariou²; Ioannis Kioumis¹

¹Pulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Exohi, Thessaloniki, Greece

²Department of Immunology – Histocompatibility, Specialized Center & Referral Center for Primary Immunodeficiencies – Paediatric Immunology, "Aghia Sophia" Children's Hospital, Athens, Greece

³Radiology Department, General Hospital Agios Pavlos, Thessaloniki

Citation: Lada M, Manika K, Spanou K, Kipourou M, Tzanoudaki M, Manika C, et al. Diagnosis of chronic granulomatous disease in an adult patient with probable miliary MDR tuberculosis. *Open J Clin Med Case Rep.* 2016; 1185

Copy right statement: Content published in the journal follows Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>). © **Lada M 2016**

Journal: Open Journal of Clinical and Medical Case Reports is an international, open access, peer reviewed Journal focusing exclusively on case reports covering all areas of clinical & medical sciences.

Visit the journal website at www.jclinmedcasereports.com

For reprints & other information, contact editorial office at info@jclinmedcasereports.com